...ame="dandell_diagnosis" /> The '''MESOMARK assay''' — measuring '''soluble mesothelin-related peptides (SMRP)''' — is the only '''FDA-approved''' blood biomarker
* '''Soluble mesothelin 0.3 nM detection limit''' — SMRP levels correlate directly with tumor volum
...
38 KB (4,854 words) - 23:25, 14 May 2026
...0px; border-bottom:1px solid #dee2e6;" | '''15 months''' before diagnosis (mesothelin + calretinin)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''0.99''' (mesothelin + fibulin-3 + HMGB1)
...
39 KB (5,126 words) - 23:25, 14 May 2026
|title=Mesothelin CAR-T Therapy for Mesothelioma: Penn huCART-meso Phase 1 and the Clinical-T
...ion=Penn Abramson Phase 1 (NCT03054298; PMID 41566776) of fully human anti-mesothelin CAR-T (huCART-meso); MSKCC intrapleural and NCI gavo-cel comparators.
...
51 KB (6,519 words) - 17:46, 24 May 2026
* '''Pleural fluid mesothelin is an adjunctive biomarker''' — elevated mesothelin in undiagnosed effusion has clinical value alongside cytology<ref name="dav
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Pleural fluid mesothelin (Davies et al., ''Am J Respir Crit Care Med'', 2009)<ref name="davies_2009"
...
27 KB (3,510 words) - 03:54, 25 May 2026
...>Adusumilli PS, Zauderer MG, Riviere I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease. ''C
...ame="cart_review">Castelletti L, Yeo D, van Zandwijk N,"; Pluschke G. Anti-mesothelin CAR T cell therapy for malignant mesothelioma. ''Biomark Res.'' 2021;9:11.
...
63 KB (8,147 words) - 05:05, 25 May 2026
...CAR-T cell therapy mesothelioma, chimeric antigen receptor T-cell therapy, mesothelin CAR-T, intrapleural CAR-T, MSKCC mesothelioma CAR-T, CAR-T clinical trials
...se rate with NAC-T cells (nanobody-armored CAR-T), the highest ORR for any mesothelin-targeted cellular therapy in mesothelioma to date.<ref name="nact" /> As of
...
71 KB (9,331 words) - 05:04, 25 May 2026
...eDIP-seq, AI pathology mesothelioma, pleural thickness staging, fibulin-3, mesothelin MESOMARK, ASCO 2025 mesothelioma guideline, IASLC mesothelioma staging
=== MESOMARK (Soluble Mesothelin-Related Peptides, SMRP) ===
...
39 KB (4,780 words) - 23:07, 14 May 2026
...or treating fields (FDA-approved under Humanitarian Device Exemption), and mesothelin-targeted CAR-T cell therapy showing a '''72% response rate''' in early-phas
* '''CAR-T cell therapy shows early promise''' — mesothelin-targeted CAR-T cells delivered intrapleurally with pembrolizumab achieved a
...
55 KB (6,941 words) - 05:05, 25 May 2026
The 53+ actively recruiting U.S. clinical trials in 2026 — including mesothelin-targeted CAR-T cell therapy, BAP1-stratified targeted approaches, and novel
...ment status (first-line vs. progression), and biomarker eligibility (BAP1, mesothelin expression, PD-L1).
...
38 KB (4,508 words) - 14:24, 21 May 2026
...vation:''' SMRP levels are typically elevated, facilitating use of soluble mesothelin-related peptide as a prognostic marker and treatment response monitor.<ref
* '''Poor Biomarker Utility:''' Mesothelin/SMRP levels are typically normal or low, limiting diagnostic biomarker util
...
41 KB (5,143 words) - 23:25, 14 May 2026
| '''Mesothelin Biomarker Accuracy''' || 61% sensitivity, 87% specificity; FDA-approved dia
| '''Mesothelin (SMRP)''' || 61% || 87% || FDA-approved diagnostic marker; most validated |
...
43 KB (5,359 words) - 23:24, 14 May 2026
...ed surveillance. The MESOMARK assay, which quantitatively measures soluble mesothelin-related peptides (SMRP) in serum, is the only FDA-cleared biomarker for mes
A large individual patient data meta-analysis found that serum mesothelin achieved a sensitivity of only 32% (95% CI: 26%–40%) at 95% specificity for
...
50 KB (6,457 words) - 23:24, 14 May 2026
...l therapy for mesothelioma and solid tumors. His phase I trial of regional mesothelin-targeted CAR T-cell therapy combined with pembrolizumab achieved a 72 perce
...ies exploiting mesothelin as a therapeutic target. He has brought multiple mesothelin-directed agents to clinic, including SS1P and LMB-100 (immunotoxins), Amatu
...
61 KB (8,018 words) - 23:25, 14 May 2026
....gov/articles/PMC8563385/ Adusumilli PS et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in
...als.gov/study/NCT06885697 Anti-Mesothelin TNaive/SCM hYP218 CAR T Cells in Mesothelin Expressing Cancers], ClinicalTrials.gov</ref>
...
111 KB (14,507 words) - 23:25, 14 May 2026
* Pioneer of mesothelin-targeted CAR T-cell therapy for mesothelioma
The most significant innovation at MSK is the development of mesothelin-targeted CAR T-cell therapy. This approach:
...
29 KB (3,638 words) - 23:25, 14 May 2026
...AUC 0.99 in training set but 0.87 on independent validation; comparable to mesothelin; Pass et al. 2012, NEJM<ref name="pmc_fibulin" />
=== MESOMARK (Soluble Mesothelin-Related Peptides / SMRP) ===
...
58 KB (7,639 words) - 23:25, 14 May 2026
* '''Soluble Mesothelin-Related Peptides (SMRP / MESOMARK)''' — the only U.S. Food and Drug Adminis
| '''Approved biomarker''' || Soluble Mesothelin-Related Peptides (SMRP / MESOMARK), FDA-cleared for monitoring biphasic and
...
54 KB (6,833 words) - 18:35, 25 May 2026
...py modifies patients' own T-cells to recognize and attack cells expressing mesothelin, a protein highly overexpressed in mesothelioma. Several constructs are in
...-T:''' Memorial Sloan Kettering launched a phase I trial in 2025 combining mesothelin-targeted CAR-T with an anti-PD-1 component
...
38 KB (4,762 words) - 23:25, 14 May 2026
...ce; for example, in the Adusumilli et al. (2021) phase I trial of regional mesothelin-targeted CAR-T plus pembrolizumab in malignant pleural disease, CAR-T cell
...66984/]. First-in-human phase I trial of regionally delivered, autologous, mesothelin-targeted CAR-T (iCasp9 M28z construct) in malignant pleural disease; CAR-T
...
36 KB (4,576 words) - 21:55, 25 May 2026
* '''Clinical trials''' for CAR-T (mesothelin-targeted), TEAD inhibitors, and novel checkpoint combinations actively enro
...ptive cell therapy using genetically modified T cells directed against the mesothelin antigen expressed by mesothelioma
...
42 KB (5,664 words) - 14:51, 26 May 2026
